Drug intelligence / Profile preview

GelTears

Development stage: Unknown
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Ophthalmic

Overview

GelTears is an ophthalmic carbomer-based gel primarily used for the treatment of dry eye syndrome. Its mechanism involves increasing the viscosity of the tear film and enhancing the precorneal residence time of its components, thereby extending the contact of solutes or suspended solids with the corneal surface. The formulation contains carbomer 940, which contributes to its gel properties and prolonged ocular retention.

Brand names: GelTears

Beyond the preview

Go deeper on GelTears.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GelTears.

Explore the full profile